Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2020-11-29 AGM Information
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Chairman & CEO Address to Shareholders 43 pages 5.2MB
AGM Information Classification · 95% confidence The document is titled '2020 Annual General Meeting' and includes a Chairman's Address to the 2020 AGM, detailed discussion of company progress, clinical trials, capital raising, and commercialisation plans. It also contains a CEO presentation with scientific and clinical data about the company's drug candidates. The content is focused on the AGM event and related presentations rather than a full annual report or financial statements. The document length is about 15,000 characters, which is consistent with detailed AGM materials. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER). The presence of the Chairman's address and CEO presentation specifically for the AGM strongly indicates this is AGM Information (AGM-R).
2020-11-29 English
Results of Annual General Meeting 2 pages 366.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the results of an Annual General Meeting (AGM) held by Vectus Biosystems Limited on 30 November 2020. It details the resolutions voted on, the proxy votes, and the outcomes of each resolution. The content focuses on the voting results rather than the full AGM materials or presentations. The document length is 3097 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-11-29 English
Vectus completes $7 million placement 2 pages 380.2KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 20 November 2020 regarding a $7 million placement of new shares to institutional and sophisticated investors. It details the number of shares issued, the price per share, the use of proceeds, and mentions the upcoming Annual General Meeting (AGM) for approvals. The text focuses on fundraising activities and capital structure changes, with no financial statements or detailed financial performance data. The document length is 4460 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Capital/Financing Update (CAP).
2020-11-19 English
Proposed issue of Securities - VBS 5 pages 28.7KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Vectus Biosystems Limited regarding a proposed issue of securities, specifically a placement of ordinary fully paid shares. It details the number of securities to be issued, the issue price, approvals required, and the purpose of the capital raising. There are no financial statements or detailed financial performance data included, and the document is focused on informing the market about the capital raising event. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2020-11-19 English
Trading Halt 2 pages 172.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Vectus Biosystems Limited regarding a trading halt requested pending a material fundraising announcement. It references ASX Listing Rule 17.1 and states the halt is until the announcement is made. The document does not contain financial statements or detailed fundraising information, only the request for a trading halt. It is short (1996 characters) and serves as a notification rather than a report or detailed update. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to fundraising activity, but since it is only a trading halt request pending a fundraising announcement, it is more accurately a Regulatory Filing (RNS) as a general regulatory announcement and compliance document. Given the content and length, the classification is Regulatory Filings (RNS).
2020-11-18 English
Notice of Annual General Meeting / Proxy Form 18 pages 798.4KB
AGM Information Classification · 95% confidence The document is titled '2020 Annual General Meeting' and contains detailed information about the AGM of Vectus Biosystems Limited, including the date, virtual meeting details, agenda items, resolutions to be voted on, proxy voting instructions, and explanatory notes. It references the Annual Report and Financial Statements as items to be received and considered but does not contain the actual financial statements or reports themselves. The document is a notice and explanatory material for the AGM, including resolutions related to director elections, remuneration report adoption, share issues, and incentive plans. It is not the Annual Report (10-K), nor an earnings release or financial supplement. It is not a voting results declaration or a proxy solicitation statement but rather the official notice and agenda for the AGM. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length (15,000 characters) and content confirm it is a full AGM notice and explanatory notes, not just a brief announcement or proxy form. Confidence is high due to clear identification of the document as an AGM notice with detailed agenda and resolutions.
2020-11-01 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.